No Data
No Data
INFN, VYGR and AMSC Are Among After Hour Movers
Fulcrum Therapeutics Raised to Buy From Neutral by Goldman Sachs
Fulcrum Therapeutics Raised to Buy From Neutral by Goldman Sachs
Express News | Goldman Sachs Upgrades Fulcrum Therapeutics to Buy, Announces $15 Price Target
Fulcrum Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 87.5% Goldman Sachs → $15 Upgrades Neutral → Buy 03/13/2024 75% RBC Capital → $14 Initiates Cov
Buy Rating Upheld for Fulcrum Therapeutics Amid Sanofi Partnership and Upcoming Trial Catalysts
Earnings Call Summary | Fulcrum Therapeutics(FULC.US) Q1 2024 Earnings Conference
The following is a summary of the Fulcrum Therapeutics, Inc. (FULC) Q1 2024 Earnings Call Transcript:Financial Performance:Fulcrum Therapeutics reported a net loss of $26.9 million for Q1 2024, compar